nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—BGLAP—embryo—colon cancer	0.128	0.2	CbGeAlD
Phylloquinone—BGLAP—renal system—colon cancer	0.0965	0.151	CbGeAlD
Phylloquinone—GGCX—renal system—colon cancer	0.0942	0.148	CbGeAlD
Phylloquinone—GGCX—digestive system—colon cancer	0.0773	0.121	CbGeAlD
Phylloquinone—BGLAP—bone marrow—colon cancer	0.073	0.114	CbGeAlD
Phylloquinone—GGCX—vagina—colon cancer	0.0682	0.107	CbGeAlD
Phylloquinone—GGCX—liver—colon cancer	0.0576	0.0902	CbGeAlD
Phylloquinone—GGCX—lymph node—colon cancer	0.0441	0.0691	CbGeAlD
Phylloquinone—Necrosis—Fluorouracil—colon cancer	0.0163	0.0493	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Irinotecan—colon cancer	0.0147	0.0444	CcSEcCtD
Phylloquinone—Inflammation—Fluorouracil—colon cancer	0.0132	0.0399	CcSEcCtD
Phylloquinone—Injection site pain—Capecitabine—colon cancer	0.0109	0.0331	CcSEcCtD
Phylloquinone—Swelling—Fluorouracil—colon cancer	0.0105	0.0318	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Irinotecan—colon cancer	0.01	0.0303	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Capecitabine—colon cancer	0.00982	0.0297	CcSEcCtD
Phylloquinone—Cyanosis—Methotrexate—colon cancer	0.0094	0.0284	CcSEcCtD
Phylloquinone—Inflammation—Capecitabine—colon cancer	0.00921	0.0279	CcSEcCtD
Phylloquinone—Injection site reaction—Capecitabine—colon cancer	0.00888	0.0269	CcSEcCtD
Phylloquinone—Necrosis—Methotrexate—colon cancer	0.00847	0.0256	CcSEcCtD
Phylloquinone—Sweating increased—Irinotecan—colon cancer	0.00816	0.0247	CcSEcCtD
Phylloquinone—Phlebitis—Capecitabine—colon cancer	0.00753	0.0228	CcSEcCtD
Phylloquinone—Swelling—Capecitabine—colon cancer	0.00735	0.0222	CcSEcCtD
Phylloquinone—Sweating—Vincristine—colon cancer	0.00735	0.0222	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Methotrexate—colon cancer	0.00731	0.0221	CcSEcCtD
Phylloquinone—Sweating—Irinotecan—colon cancer	0.00716	0.0217	CcSEcCtD
Phylloquinone—Inflammation—Methotrexate—colon cancer	0.00686	0.0207	CcSEcCtD
Phylloquinone—Flushing—Irinotecan—colon cancer	0.00622	0.0188	CcSEcCtD
Phylloquinone—Immune system disorder—Irinotecan—colon cancer	0.00605	0.0183	CcSEcCtD
Phylloquinone—Erythema—Fluorouracil—colon cancer	0.00559	0.0169	CcSEcCtD
Phylloquinone—Sweating increased—Capecitabine—colon cancer	0.00546	0.0165	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Methotrexate—colon cancer	0.00499	0.0151	CcSEcCtD
Phylloquinone—Anaphylactic shock—Vincristine—colon cancer	0.00489	0.0148	CcSEcCtD
Phylloquinone—Anaphylactic shock—Irinotecan—colon cancer	0.00476	0.0144	CcSEcCtD
Phylloquinone—Hyperhidrosis—Vincristine—colon cancer	0.00473	0.0143	CcSEcCtD
Phylloquinone—Hyperhidrosis—Irinotecan—colon cancer	0.0046	0.0139	CcSEcCtD
Phylloquinone—Hypotension—Vincristine—colon cancer	0.00457	0.0138	CcSEcCtD
Phylloquinone—Anaphylactic shock—Fluorouracil—colon cancer	0.00456	0.0138	CcSEcCtD
Phylloquinone—Hypotension—Irinotecan—colon cancer	0.00445	0.0135	CcSEcCtD
Phylloquinone—Hypotension—Fluorouracil—colon cancer	0.00426	0.0129	CcSEcCtD
Phylloquinone—Dyspnoea—Irinotecan—colon cancer	0.00425	0.0128	CcSEcCtD
Phylloquinone—Pain—Vincristine—colon cancer	0.00418	0.0126	CcSEcCtD
Phylloquinone—Flushing—Capecitabine—colon cancer	0.00416	0.0126	CcSEcCtD
Phylloquinone—Pain—Irinotecan—colon cancer	0.00407	0.0123	CcSEcCtD
Phylloquinone—Dyspnoea—Fluorouracil—colon cancer	0.00407	0.0123	CcSEcCtD
Phylloquinone—Immune system disorder—Capecitabine—colon cancer	0.00405	0.0123	CcSEcCtD
Phylloquinone—Erythema—Capecitabine—colon cancer	0.00391	0.0118	CcSEcCtD
Phylloquinone—Pain—Fluorouracil—colon cancer	0.0039	0.0118	CcSEcCtD
Phylloquinone—Hypersensitivity—Vincristine—colon cancer	0.0036	0.0109	CcSEcCtD
Phylloquinone—Sweating—Methotrexate—colon cancer	0.00357	0.0108	CcSEcCtD
Phylloquinone—Hypersensitivity—Irinotecan—colon cancer	0.00351	0.0106	CcSEcCtD
Phylloquinone—Hypersensitivity—Fluorouracil—colon cancer	0.00336	0.0102	CcSEcCtD
Phylloquinone—Dizziness—Vincristine—colon cancer	0.00323	0.00978	CcSEcCtD
Phylloquinone—Dizziness—Irinotecan—colon cancer	0.00315	0.00953	CcSEcCtD
Phylloquinone—Hyperhidrosis—Capecitabine—colon cancer	0.00308	0.00932	CcSEcCtD
Phylloquinone—Immune system disorder—Methotrexate—colon cancer	0.00302	0.00912	CcSEcCtD
Phylloquinone—Dizziness—Fluorouracil—colon cancer	0.00302	0.00912	CcSEcCtD
Phylloquinone—Hypotension—Capecitabine—colon cancer	0.00298	0.00901	CcSEcCtD
Phylloquinone—Erythema—Methotrexate—colon cancer	0.00291	0.00879	CcSEcCtD
Phylloquinone—Dyspnoea—Capecitabine—colon cancer	0.00284	0.00859	CcSEcCtD
Phylloquinone—Pain—Capecitabine—colon cancer	0.00273	0.00824	CcSEcCtD
Phylloquinone—Anaphylactic shock—Methotrexate—colon cancer	0.00237	0.00718	CcSEcCtD
Phylloquinone—Hypersensitivity—Capecitabine—colon cancer	0.00235	0.0071	CcSEcCtD
Phylloquinone—Hyperhidrosis—Methotrexate—colon cancer	0.00229	0.00694	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—FGFR3—colon cancer	0.00222	0.0714	CbGpPWpGaD
Phylloquinone—Hypotension—Methotrexate—colon cancer	0.00222	0.00671	CcSEcCtD
Phylloquinone—Dyspnoea—Methotrexate—colon cancer	0.00212	0.0064	CcSEcCtD
Phylloquinone—Dizziness—Capecitabine—colon cancer	0.00211	0.00638	CcSEcCtD
Phylloquinone—Pain—Methotrexate—colon cancer	0.00203	0.00614	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—BAX—colon cancer	0.00191	0.0616	CbGpPWpGaD
Phylloquinone—GGCX—Post-translational protein modification—MUC2—colon cancer	0.00189	0.0609	CbGpPWpGaD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCND1—colon cancer	0.00189	0.0609	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—CDH1—colon cancer	0.00187	0.0603	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Methotrexate—colon cancer	0.00175	0.00529	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—colon cancer	0.00174	0.056	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—PPARG—colon cancer	0.00167	0.0539	CbGpPWpGaD
Phylloquinone—Dizziness—Methotrexate—colon cancer	0.00157	0.00475	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—SRC—colon cancer	0.00147	0.0474	CbGpPWpGaD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—EP300—colon cancer	0.00144	0.0463	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—TGFB1—colon cancer	0.00132	0.0424	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—SRC—colon cancer	0.00125	0.0403	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CCND1—colon cancer	0.00119	0.0383	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN1A—colon cancer	0.00115	0.0371	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—EP300—colon cancer	0.00109	0.0353	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—CDX2—colon cancer	0.00106	0.034	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—HRAS—colon cancer	0.00104	0.0334	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—CDKN1A—colon cancer	0.000967	0.0312	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—PIK3CA—colon cancer	0.000951	0.0306	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—EP300—colon cancer	0.00092	0.0296	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—AKT1—colon cancer	0.000915	0.0295	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—MUC2—colon cancer	0.000897	0.0289	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—AKT1—colon cancer	0.000777	0.025	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—TP53—colon cancer	0.000659	0.0212	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—AKT1—colon cancer	0.000556	0.0179	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—CTNNB1—colon cancer	0.000208	0.00669	CbGpPWpGaD
